In August 2024, KJ Muldoon was born with a death sentence encoded in his DNA—a single broken letter among three billion that left his body unable to process protein. Six months later, he walked out of Children's Hospital of Philadelphia, cured by a gene-editing therapy designed, manufactured, approved, and delivered in 180 days.
Genetic medicine now moves at software speed—a paradigm shift from incremental progress. The FDA cleared a regulatory pathway that could approve therapies after testing on as few as 5-10 patients. Academic labs can now develop treatments for diseases affecting single children, but the bottleneck is scaling, not science.
18 events
Latest: December 10th, 2025 · 6 months ago
Showing 8 of 18
JK to step
Tap a bar to jump to that date
Jump to
December 2025
KJ Named to Nature's 10
LatestRecognition
Nature magazine named KJ Muldoon to list of ten people who shaped science in 2025 as the 'Trailblazing baby'—first person saved by personalized CRISPR gene editing.
November 2025
FDA Announces Plausible Mechanism Pathway
Regulatory Innovation
Makary and Prasad published framework in NEJM enabling approval of personalized therapies with 5-10 patients when biological mechanism is understood. Could enable liver/blood gene editing approvals within 3 years. Cited KJ's case as proof of concept.
Umbrella Trial Framework Agreed
Regulatory
CHOP-Penn team reached agreement with FDA on umbrella trial design treating 7 different urea cycle disorders with same gene editing platform as single drug. Dramatically streamlines approval process for multiple genetic variants.
CRISPR Cholesterol Trial Shows Promise
Research
Musunuru's team published results from CTX310 trial: CRISPR base editing safely reduced LDL cholesterol and triglycerides in 15 patients with treatment-resistant lipid disorders. No serious adverse events.
June 2025
KJ Discharged from Hospital
Patient Milestone
After 307 days in hospital, KJ went home healthy. Tolerating normal protein intake, growing well, hitting developmental milestones. First personalized gene editing patient successfully treated and released.
May 2025
Results Published in NEJM
Publication
Team published 'Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease' in New England Journal of Medicine, documenting first successful personalized CRISPR therapy.
April 2025
Treatment Course Completed
Treatment
Third and final dose completed seven-week infusion regimen. KJ showed stable ammonia levels, tolerated increased dietary protein, and achieved 50% reduction in nitrogen-scavenger medication without significant side effects.
March 2025
Second Dose Administered
Treatment
KJ received second infusion of personalized base editor as part of three-dose regimen (FDA limit for expanded-access protocol).
February 2025
First Personalized CRISPR Therapy Delivered
Treatment Milestone
KJ received first dose of customized lipid nanoparticle-delivered base editing therapy at 6 months old. Therapy designed to correct single faulty DNA letter among 3 billion. Historic first for on-demand gene editing.
FDA Clears Expanded-Access Application
Regulatory
FDA processed single-patient expanded-access IND in approximately one week—extraordinarily fast for investigational drug approval. Cleared path for first personalized CRISPR treatment.
September 2024
Base Editor Development Initiated
Research
CHOP-Penn team began designing bespoke adenine base editor (k-abe) targeting KJ's specific mutation. Originally estimated 18 months; team compressed timeline to 6 months with collaboration from Integrated DNA Technologies.
August 2024
KJ Transferred to CHOP
Patient
Within days of birth, KJ transferred to Children's Hospital of Philadelphia. Team led by Ahrens-Nicklas and Musunuru identified specific CPS1 variant and began evaluating personalized treatment options.
KJ Muldoon Born with CPS1 Deficiency
Patient
Born in Pennsylvania with severe carbamoyl phosphate synthetase 1 deficiency. DNA sequenced immediately, revealing mutations in both copies of CPS1 gene causing inability to process protein.
December 2023
FDA Approves First CRISPR Therapy
Regulatory Milestone
FDA approved Casgevy for sickle cell disease—first CRISPR therapy authorized in US. Ex vivo editing of patient blood stem cells. Approximately 16,000 patients eligible.
November 2023
UK Approves Casgevy
Regulatory Milestone
First CRISPR-based therapy approved anywhere in world. UK MHRA cleared Casgevy for sickle cell disease and beta-thalassemia in patients 12+ with recurrent crises.
May 2019
Zolgensma Approved for Spinal Muscular Atrophy
Commercial
Second FDA-approved AAV gene therapy. One-time treatment for SMA in children under 2. Demonstrated feasibility of treating severe pediatric genetic diseases with single-dose gene delivery.
December 2017
FDA Approves Luxturna
Regulatory Milestone
First FDA-approved gene therapy for inherited disease (retinal dystrophy). Used AAV vector to deliver functional RPE65 gene. Opened door for genetic medicines targeting rare disorders.
September 1999
Jesse Gelsinger Dies in Gene Therapy Trial
Regulatory Setback
18-year-old with mild OTC deficiency (same urea cycle disorder family as CPS1) died from immune response to adenoviral vector. All US gene therapy trials halted. Led to decades of increased regulatory scrutiny.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
1999
Jesse Gelsinger's Death (1999)
Jesse Gelsinger, 18, died four days after receiving gene therapy for ornithine transcarbamylase (OTC) deficiency—a urea cycle disorder like KJ's CPS1 deficiency. He suffered catastrophic immune response to the adenoviral vector. Investigations revealed unreported adverse events from prior research and conflicts of interest involving the lead scientist. FDA shut down the University of Pennsylvania's gene therapy program.
Then
All US gene therapy trials halted. Field entered 'ice age' lasting years. Regulatory oversight dramatically intensified.
Now
Created modern framework for gene therapy safety monitoring and conflict-of-interest disclosure. Memory of Gelsinger's death made FDA cautious for two decades—making current rapid approval of KJ's therapy even more remarkable departure.
Why this matters now
Both cases involve urea cycle disorders and young patients. Gelsinger's death from viral vector immune response drove development of safer delivery methods like the lipid nanoparticles used for KJ. His tragedy created the regulatory caution that had to be overcome—and the safety standards that made KJ's treatment possible.
2 of 3
2017-2019
First Gene Therapy Approvals (2017-2019)
FDA approved Luxturna (2017) for inherited blindness and Zolgensma (2019) for spinal muscular atrophy—first gene therapies for inherited diseases. Both used AAV vectors and went through traditional clinical trials with accelerated approval pathways based on small patient numbers. Demonstrated that FDA would approve transformative therapies for rare pediatric conditions with limited trial data when benefit-risk was compelling.
Then
Opened door for genetic medicines. Showed viable business model for ultra-rare diseases. Gene therapy investing surged.
Now
Established precedent for small-N approvals that paved way for plausible mechanism pathway. Proved safety of AAV vectors in humans, though lipid nanoparticles subsequently emerged as alternative addressing immunogenicity concerns.
Why this matters now
These approvals represented first generation: standardized therapies tested traditionally. KJ's case represents next evolution: fully personalized, faster development, novel regulatory pathway. Shows trajectory from 'one drug for one disease' to 'custom drugs for individual mutations.'
3 of 3
2023
Casgevy CRISPR Approval (2023)
In November-December 2023, UK and FDA approved Casgevy for sickle cell disease—first CRISPR-based therapy ever authorized. Ex vivo treatment: patients' blood stem cells edited outside body, then reinfused. Went through traditional phase 1/2/3 trials over multiple years with rigorous safety monitoring. By end of 2024, over 50 patients treated at 50 global centers.
Then
Validated CRISPR as therapeutic modality, not just research tool. Approximately 16,000 US patients became eligible for functional cure of genetic disease.
Now
Established regulatory template for CRISPR therapies. Demonstrated that precise gene editing could be done safely in humans with durable effects. Created proof point that emboldened FDA to consider accelerated pathways for next-generation applications.
Why this matters now
Casgevy proved CRISPR works and is safe—essential predicate for FDA to approve KJ's personalized treatment on compressed timeline. But Casgevy is standardized product tested in hundreds of patients over years. KJ's therapy was bespoke, developed in six months, tested in one patient. Casgevy made KJ possible by validating the underlying technology; KJ shows where the technology goes next.
